AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results showed promise again rival drugs from Merck and NewAmsterdam Pharma, but AstraZeneca stock fell in line ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of standard-of-care statin therapy, as compared with placebo. AZD0780 is an ...

AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.

AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal investigations.

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...